MedPath

A Study Evaluating Safety and Efficacy of BIOD-123 Compared to Insulin Lispro (Humalog®)

Phase 2
Completed
Conditions
Type 1 Diabetes Mellitus
Interventions
Drug: Lispro (Humalog)
Registration Number
NCT01686620
Lead Sponsor
Biodel
Brief Summary

The purpose of this study is to evaluate the safety and efficacy of BIOD-123 compared to insulin lispro (Humalog®) when used as part of a basal-bolus regimen in patients with type 1 diabetes.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
132
Inclusion Criteria
  • Established clinical diagnosis of type 1 diabetes, consistent with ADA classification criteria (Diabetes Care 35: S64-S71, 2012), for more than 1 year.
  • Age: 18 years old, or older.
  • Body Mass Index: between 18 and 35 kg/m2, inclusive.
  • Willing to use insulin glargine as the only basal insulin throughout the duration of the trial.
  • Willingness not to use insulin pump treatment and only use the study glucose meter and CGM devices during the duration of the trial.
Exclusion Criteria
  • History of known hypersensitivity to any of the components in the study medication
  • Treatment with pramlintide or GLP-1 analogs within 30 days of screening or anticipated use of these medications during the course of the study.
  • Treatment with oral or intravenous corticosteroids in the last 3 months prior to screening. Standard doses of inhalational corticosteroid used as part of a long term treatment regimen are allowed.
  • Consistent recent hypoglycemic unawareness within the last six months
  • History of more than two severe hypoglycemic events within six months prior to screening

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
BIOD-123BIOD-123BIOD-123 used as prandial insulin
Lispro (Humalog)Lispro (Humalog)Lispro (Humalog) used as prandial insulin
Primary Outcome Measures
NameTimeMethod
Change in HbA1CBaseline and 18 week treatment period
Secondary Outcome Measures
NameTimeMethod
Hypoglycemic event ratesBaseline and 18 week treatment period
Insulin doseBaseline and 18 week treatment period
Daily blood glucose measuresBaseline and 18 week treatment period

Trial Locations

Locations (33)

Anaheim Clinical Trials, LLC

🇺🇸

Anaheim, California, United States

Baylor Endocrine Center

🇺🇸

Dallas, Texas, United States

Desert Endocrinolgy

🇺🇸

Henderson, Nevada, United States

Mountain Diabetes & Endrocrine Center

🇺🇸

Dallas, Texas, United States

Dallas Diabetes and Endocrine Research Center

🇺🇸

Dallas, Texas, United States

Profil Research Institute

🇺🇸

Chula Vista, California, United States

Rocky Mountain Diabetes and Osteoporosis Center PA

🇺🇸

Idaho Falls, Idaho, United States

Research Institute of Dallas

🇺🇸

Dallas, Texas, United States

Monteagle Medical Center

🇺🇸

San Francisco, California, United States

University of Miami Diabetes Research Institute

🇺🇸

Miami, Florida, United States

Henry Ford Health System

🇺🇸

Detroit, Michigan, United States

Sentral Clinical Research Services, LLC

🇺🇸

Cincinnati, Ohio, United States

Oregon Health Sciences University

🇺🇸

Portland, Oregon, United States

Sonterra Clinical Research

🇺🇸

San Antonio, Texas, United States

The Center for Diabetes and Endocrine Care

🇺🇸

Hollywood, Florida, United States

John Muir Physician Network Clinical Research Center

🇺🇸

Concord, California, United States

Mills-Peninsula Health Services

🇺🇸

San Mateo, California, United States

Scripps Whittier Diabetes Institute

🇺🇸

La Jolla, California, United States

Providence Clinical Research Pharmaseek

🇺🇸

North Hollywood, California, United States

Private Practice - Richard Cherlin, MD.

🇺🇸

Los Gatos, California, United States

Progressive Medical Research Pharmaseek

🇺🇸

Port Orange, Florida, United States

Atlanta Diabetes Associates

🇺🇸

Atlanta, Georgia, United States

Kentucky Diabetes

🇺🇸

Lexington, Kentucky, United States

MidAmerica Diabetes Associates, PA

🇺🇸

Wichita, Kansas, United States

Diabetes & Glandular Disease Research

🇺🇸

Rockville, Maryland, United States

Mercury Street Medical

🇺🇸

Butte, Montana, United States

Diabetes & Endocrinology Consultants, PC

🇺🇸

Morehead City, North Carolina, United States

Research Foundation of SUNY Upstate Medical University

🇺🇸

Syracuse, New York, United States

Texas Diabetes and Endocrinology

🇺🇸

Round Rock, Texas, United States

Capital Clinical Research Center

🇺🇸

Olympia, Washington, United States

Ranier Clinical Research, Inc

🇺🇸

Renton, Washington, United States

Rockwood Clinic

🇺🇸

Spokane, Washington, United States

Endocrine Research Solutions

🇺🇸

Roswell, Georgia, United States

© Copyright 2025. All Rights Reserved by MedPath